Icon Plc ICLR

Zacks Investment Research 27 oct

Icon PLC reported Q3 2026 earnings of $2.66 per share, slightly beating consensus estimates of $2.64, with revenues of $2.02 billion. However, the company has underperformed the S&P 500 year-to-date, gaining only 0.9% versus the market's 12.1% gain. Despite the earnings beat, unfavorable estimate revisions ahead of the report resulted in a Zacks Rank #4 (Sell) rating, suggesting underperformance in the near term. The Medical Services industry ranks in the bottom 39% of Zacks industries.

Zacks Investment Research 22 oct

Alignment Healthcare is expected to report a quarterly loss of $0.04 per share with revenues up 31.9% year-over-year for Q3 2026. The company has a negative Earnings ESP of -37.50% and a Zacks Rank of #4 (Sell), making it unlikely to beat consensus estimates. However, the company has beaten EPS estimates in all four of the last quarters.

GlobeNewswire Inc. 21 sept

The global rare disease CRO market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030, with an 8.9% CAGR. Growth is driven by expanding gene and cell therapy pipelines, increasing orphan drug approvals, precision medicine adoption, and decentralized clinical trials. Key trends include AI integration, patient registries, and real-world evidence utilization.

Zacks Investment Research 4 sept

CVS Health reported strong Q2 2026 results with adjusted EPS of $2.58 (up 42.5% YoY) and revenues of $106.10 billion (up 7.3%), beating consensus estimates. The company raised full-year 2026 guidance for earnings and revenues. However, estimates have trended downward over the past month with a -6.08% consensus shift, and the stock received a Zacks Rank #3 (Hold) rating with expectations for in-line returns.

GlobeNewswire Inc. 5 ago

The global eClinical Solutions market is projected to grow from USD 11.50 billion in 2025 to USD 42.55 billion by 2035, at a CAGR of 13.98%. Growth is driven by increased demand for efficient clinical trials, rising chronic disease prevalence, adoption of AI and cloud computing technologies, and decentralized trial models. Key players include Oracle, Veeva Systems, IQVIA, Medidata Solutions, and IBM Watson Health.